Do you wa Abcode Ab AaabCede Normal AaBbCcDc AaBbcoded AaBhCeDdi Heading 1 Heading 2 Heading 4 No Spacing Head Cr 200,000 163,750 50.000 60,000 The following trial balance relates to Arthur at 31 December 2019: Dr Ordinary share capital (50p/share) Retained Earnings at 1 January 2019 7% loan repayable 31 December 2021 Loan interest paid 1.750 Land and buildings at cost (land element 163,000, note ) 403,000 Plant and equipment at cost (note 0 96,000 Accumulated depreciation at 1 January 2019 (Buildings) Accumulated depreciation at 1 January 2019 (Plant and equipment) Trade receivables 72,000 Inventory at 1 January 2019 44,500 Cash and cash equivalents 12,500 Trade Payables Revenue Purchases 78,500 Administrative expenses 34.000 Distribution costs 51,000 Interim dividend paid 9,500 Research and development (note (6) 24,000 Investment income 826.750 44,000 45,000 246,500 17,500 826.750 0. Non-current assets The buildings has an estimated life of 40 years when built, and are being depreciated on a straight line basis. The directors wish to incorporate a revaluation of the land and buildings as at 1 January 2019, when the fair value of the land is 200,000 and the fair value of the building is 210,000. The original estimated life remains the same. "Included in the trial balance is a plant that had cost 8,000 and had accumulated depreciation to date of 6,000. The plant was classed as held for sale from the start of the year. The plant was sold in January 2020 for 1,500, with the estate agent charging commission of 5% on the selling price. Plant and equipment is to be depreciated at 30% on a reducing balance basis. All depreciation should be charged to cost of sales. At the end of year 2019, an impairment test has identified that one of the equipment has been impaired after depreciation is recognised. The equipment was purchased with 10,000 with an accumulated depreciation of 7,000 at the year end. The company estimates that the equipment is expected to generate the following cashflows over its remaining three years useful life: Focus MacBook Pro Normal No Spacing Heading 1 Heading 2 Heading 4 oopicu aargau o male year impairment test has identified that one of the equipment has been impaired after depreciation is recognised. The equipment was purchased with 10,000 with an accumulated depreciation of 7,000 at the year end. The company estimates that the equipment is expected to generate the following cashflows over its remaining three years useful life: Page 2 of 7 Inflows (E) Outflows ) Year 1 1200 200 Year 2 1500 600 Year 3 800 300 Cashflows occur at the end of the year concerned. At the end of the three-year period, the asset is expected to be sold for 500. The discount rate is 10%. The market value of this equipment is 2500 with a delivery cost of 150. (i). Intangible assets Research and development comprises research costs of 4,000 and development costs relating to a new product totalling 20,000 (both are recorded in the trial balance sheet). Production of this began on 30 September 2019. Amortisation is to be charges at 4% a year. (). At the end of year 2019, the board has made a decision to pay dividend at 2p per share to shareholders. The dividend payment needs to be accrued in the financial statements. (iv). The revenue figure in the trial balance includes sales made on credit for January 2020 amounting to 6,000. (v). The allowance for doubtful debt is to be maintained at 5% of the ending balance of the trade receivable accounts (vi). Inventory at 31 December 2019 has a cost of 39,700 Assume that Arthur Ltd. requires the difference in depreciation charges due to revaluation to be transferred from revaluation surplus to retained earning. Section B. Fill in the blanket 1. The carrying value of building at the end of year 2019 is 2. The journal entry for note (iv) for the adjustment of the sale in January 2020 is Dr. Cr. 3. The recoverable amount of the impaired equipment is 4. According to IAS38 Intangible assets, the journal entries and the amount for the adjustment to the Research and Development balance in the trial balance sheet needed are: Dr. Cr. Amount: 5. The journal entries for the dividend distribution are: Dr. Cr. Amount: Do you wa Abcode Ab AaabCede Normal AaBbCcDc AaBbcoded AaBhCeDdi Heading 1 Heading 2 Heading 4 No Spacing Head Cr 200,000 163,750 50.000 60,000 The following trial balance relates to Arthur at 31 December 2019: Dr Ordinary share capital (50p/share) Retained Earnings at 1 January 2019 7% loan repayable 31 December 2021 Loan interest paid 1.750 Land and buildings at cost (land element 163,000, note ) 403,000 Plant and equipment at cost (note 0 96,000 Accumulated depreciation at 1 January 2019 (Buildings) Accumulated depreciation at 1 January 2019 (Plant and equipment) Trade receivables 72,000 Inventory at 1 January 2019 44,500 Cash and cash equivalents 12,500 Trade Payables Revenue Purchases 78,500 Administrative expenses 34.000 Distribution costs 51,000 Interim dividend paid 9,500 Research and development (note (6) 24,000 Investment income 826.750 44,000 45,000 246,500 17,500 826.750 0. Non-current assets The buildings has an estimated life of 40 years when built, and are being depreciated on a straight line basis. The directors wish to incorporate a revaluation of the land and buildings as at 1 January 2019, when the fair value of the land is 200,000 and the fair value of the building is 210,000. The original estimated life remains the same. "Included in the trial balance is a plant that had cost 8,000 and had accumulated depreciation to date of 6,000. The plant was classed as held for sale from the start of the year. The plant was sold in January 2020 for 1,500, with the estate agent charging commission of 5% on the selling price. Plant and equipment is to be depreciated at 30% on a reducing balance basis. All depreciation should be charged to cost of sales. At the end of year 2019, an impairment test has identified that one of the equipment has been impaired after depreciation is recognised. The equipment was purchased with 10,000 with an accumulated depreciation of 7,000 at the year end. The company estimates that the equipment is expected to generate the following cashflows over its remaining three years useful life: Focus MacBook Pro Normal No Spacing Heading 1 Heading 2 Heading 4 oopicu aargau o male year impairment test has identified that one of the equipment has been impaired after depreciation is recognised. The equipment was purchased with 10,000 with an accumulated depreciation of 7,000 at the year end. The company estimates that the equipment is expected to generate the following cashflows over its remaining three years useful life: Page 2 of 7 Inflows (E) Outflows ) Year 1 1200 200 Year 2 1500 600 Year 3 800 300 Cashflows occur at the end of the year concerned. At the end of the three-year period, the asset is expected to be sold for 500. The discount rate is 10%. The market value of this equipment is 2500 with a delivery cost of 150. (i). Intangible assets Research and development comprises research costs of 4,000 and development costs relating to a new product totalling 20,000 (both are recorded in the trial balance sheet). Production of this began on 30 September 2019. Amortisation is to be charges at 4% a year. (). At the end of year 2019, the board has made a decision to pay dividend at 2p per share to shareholders. The dividend payment needs to be accrued in the financial statements. (iv). The revenue figure in the trial balance includes sales made on credit for January 2020 amounting to 6,000. (v). The allowance for doubtful debt is to be maintained at 5% of the ending balance of the trade receivable accounts (vi). Inventory at 31 December 2019 has a cost of 39,700 Assume that Arthur Ltd. requires the difference in depreciation charges due to revaluation to be transferred from revaluation surplus to retained earning. Section B. Fill in the blanket 1. The carrying value of building at the end of year 2019 is 2. The journal entry for note (iv) for the adjustment of the sale in January 2020 is Dr. Cr. 3. The recoverable amount of the impaired equipment is 4. According to IAS38 Intangible assets, the journal entries and the amount for the adjustment to the Research and Development balance in the trial balance sheet needed are: Dr. Cr. Amount: 5. The journal entries for the dividend distribution are: Dr. Cr. Amount